Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01381796 · ClinicalTrials.gov registry record · Phase 1

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

A Phase 1 study, sponsored by NuPathe.

Completed
Registry status
Phase 1
Development phase
63
Enrollment target

NCT01381796 is a Phase 1 study that has completed, run by NuPathe. The registered enrollment target is 63 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01381796, a Phase 1 study, has completed, sponsored by NuPathe.

COMPLETED
Registry status
Phase 1
Development phase
63 participants
Enrollment target

Study Summary

The purpose of this research is to: 1. Compare two study patches having minor differences in patch components 2. Compare the pharmacokinetics (PK - how the body absorbs, metabolizes and eliminates medication) of NP101 (study patches) versus a currently approved oral formulation of Imitrex 3. Collect resistance data during application of NP101 (study patch)

Interventions

  • DRUG NP101
  • DRUG sumatriptan succinate

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2009-12
Est. Completion 2010-09
Phase Phase 1

Sponsor

NuPathe

7 total trials

What the Registry Record Tells You About NCT01381796

The ClinicalTrials.gov registry entry for NCT01381796 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuPathe, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which NP101 is the first listed.

NCT01381796 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01381796 about?

NCT01381796 is a clinical study titled "Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults". The purpose of this research is to: 1. Compare two study patches having minor differences in patch components 2. Compare the pharmacokinetics (PK - how the body absorbs, metabolizes and eliminates medication) of NP101 (study patches) versus a currently approved oral formulation of Imitrex 3. Collec...

What is the current status of trial NCT01381796?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2009-12. Estimated completion is 2010-09.

What interventions are being tested in trial NCT01381796?

The interventions under investigation include: NP101 (DRUG), sumatriptan succinate (DRUG).

Who is sponsoring clinical trial NCT01381796?

This trial is sponsored by NuPathe, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.